Immunogenicity Induced by COVID-19 Vaccines in Mexican Population: mRNA Expression for IgG Anti-spike
This observational study, sponsored by the National Polytechnic Institute in Mexico, aimed to assess the immunogenicity of four COVID-19 vaccines (Oxford/AstraZeneca, Sputnik V, Pfizer/BioNTech, and Sinovac) in the Mexican population. The findings could provide valuable insights into the comparative effectiveness of these vaccines, potentially influencing public health policies and vaccine distribution strategies in Mexico and similar markets. Given the ongoing global focus on COVID-19 vaccination and booster strategies, the results may also have implications for future vaccine development and market positioning. The completion of this study suggests readiness for data dissemination, which could attract interest from pharmaceutical companies and public health organizations looking to enhance vaccine efficacy and safety profiles.
Indication: COVID-19 Vaccine
Modality: RNA therapy
Target: Gene expression of IgG anti-spike protein induced by COVID-19 vaccines.
Sponsor: National Polytechnic Institute, Mexico
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Gene expression of IgG anti-spike protein induced by COVID-19 vaccines.
View original source fields
Condition raw: COVID-19 Vaccine
Condition normalized: COVID-19 Vaccine
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Gene expression of IgG anti-spike protein induced by COVID-19 vaccines.
Target normalized: Gene expression of IgG anti-spike protein induced by COVID-19 vaccines.